Gujarat Themis Biosyn Limited (GTBL) has marked a significant milestone in its growth trajectory with the commencement of commercial production at its expanded Fermentation Block in Vapi, Gujarat. The company officially began production of Rifamycin-S and Rifamycin-O on October 18, 2025, signaling a substantial boost to its manufacturing capabilities.

Capacity Expansion Details

The expansion project has more than doubled GTBL's fermentation capacity, as detailed in the following table:

This significant increase in capacity positions GTBL to capitalize on growth opportunities within the fermentation segment, particularly in the production of multiple fermentation products.

Strategic Implications

The expansion of the Fermentation Block at Vapi carries several strategic implications for GTBL:

1. Enhanced Production Capabilities: The more than doubled capacity allows GTBL to significantly increase its output of fermentation products.
2. Product Diversification: The expanded facilities enable the company to produce a wider range of fermentation products, potentially opening new market opportunities.
3. Market Position: With increased capacity, GTBL is better positioned to meet growing market demand and potentially increase its market share in the fermentation segment.
4. Operational Efficiency: The new facilities may lead to improved operational efficiencies and economies of scale.

Company's Statement

In its official communication to the stock exchanges, GTBL stated, "With this capacity expansion, the Company is in a strong position to capitalise on the significant growth opportunities in the fermentation segment."

The commencement of commercial production at the expanded facility marks a pivotal moment for Gujarat Themis Biosyn Limited. As the company leverages its enhanced manufacturing capabilities, stakeholders will be keenly watching how this translates into business growth and market performance in the coming quarters.

Gujarat Themis Biosyn Limited , a prominent player in the pharmaceutical intermediates sector, has released its financial results for the first quarter of fiscal year 2026, along with several key corporate announcements.

Financial Performance

The company reported a total income of ₹3,614.72 lakh for the quarter ended June 30, 2025, compared to ₹3,935.17 lakh in the same quarter of the previous year. Despite the slight decrease in revenue, Gujarat Themis Biosyn maintained strong profitability, with a net profit after tax of ₹926.16 lakh. This represents a decrease from the ₹1,323.62 lakh reported in the corresponding quarter of the previous year.

Dividend Record Date

The board of directors has set September 5, 2025, as the record date for determining shareholder eligibility for dividend distribution for the financial year ended March 31, 2025.

Board Composition Changes

Gujarat Themis Biosyn announced significant changes to its board composition:

• New Appointment: Mr. Nihar Parikh has been appointed as an Additional Non-Executive Independent Director, effective August 15, 2025. Parikh, an entrepreneur turned Venture Capitalist, brings valuable experience from his role as CEO of ZCL Chemicals Limited and his current position as founder of 4Point0 Health Ventures.

• Director Cessation: Mr. Siddharth Kusumgar will conclude his tenure as an Independent Director on September 20, 2025, upon completing his second consecutive term.

• Committee Restructuring: Following these changes, Mr. Parikh will replace Mr. Kusumgar on all board committees, including Audit, Nomination & Remuneration, Corporate Social Responsibility, Stakeholders Relationship, and Risk Management Committees, effective September 20, 2025.

New API Plant Commences Operations

In a significant development for the company's growth strategy, Gujarat Themis Biosyn announced the commencement of commercial production at its new Active Pharmaceutical Ingredients (API) plant in Vapi, Gujarat, on May 1, 2025. This state-of-the-art facility is designed to manufacture APIs and intermediates for the pharmaceutical industry, strengthening the company's position in both domestic and export markets, particularly in the United States and Europe.

The new plant is expected to support Gujarat Themis Biosyn's forward integration initiatives and enhance its capabilities in producing fermentation-based pharmaceutical intermediates, which remains the company's core focus.

Gujarat Themis Biosyn's strategic decisions, including the new plant operation and board restructuring, reflect its commitment to growth and adaptation in the evolving pharmaceutical landscape. As the company continues to focus on its strengths in fermentation-based products, investors and industry observers will be keen to watch its performance in the coming quarters.